Advaxis and Merck have formed a partnership to conduct a clinical trial with their experimental prostate cancer drugs

Advaxis and Merck Partnership for Immunotherapy Prostate Cancer Drug Trial

Advaxis and Merck have formed a partnership to conduct a clinical trial with their experimental prostate cancer drugs Advaxis and Merck have formed a partnership to test their experimental prostate cancer drugs, ADXS-PSA and anti PD-1 antibody pembrolizumab, to see if the combination of these two drugs will yield psoitive results in a phase I/II trial in prostate cancer patients who …

Advaxis and Merck Form Collaboration to Evaluate Investigational Combination of Two Novel Immunotherapy Candidates for Advanced Prostate Cancer

August 25th, 2014 Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, has entered into a clinical trial collaboration agreement with Merck, known as MSD outside the United States and Canada, through its subsidiaries, to evaluate the combination of Advaxis’s Lm-LLO cancer immunotherapy, ADXS-PSA, with Merck’s investigational anti PD-1 antibody, pembrolizumab. The planned clinical trial will evaluate the safety and efficacy …

Sipuleucel-T: An Autologous Cellular Immunotherapy for Patients with Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer

Dr Andy Stubbs the Senior Medical Director at Dendreon joined us at the World Vaccine Congress Washington to talk to us about Sipuleucel-T, an autologous Cellular Immunotherapy for patients with asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer. Dr Stubbs guided us through the following: Introduction to prostate cancer Natural History of Prostate Cancer Overview of sipuleucel-T & Pre-clinical …